Global Type 1 Diabetes Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Co, Novo Nordisk and Sanofi-Aventis
DUBLIN, July 18, 2014 /PRNewswire/ –
Research and Markets (
http://www.researchandmarkets.com/research/3txjqf/global_type_1) has announced the
addition of the “Global Type 1 Diabetes Market 2014-2018″
[http://www.researchandmarkets.com/research/3txjqf/global_type_1 ] report to their
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels.
In this condition, the immune system is activated against self-insulin producing cells.
This, in turn, hampers the body’s ability to produce insulin and disrupts blood glucose
homeostasis. Type 1 diabetes T1D differs from the more common form of diabetes mellitus,
Type 2 diabetes, as people with Type 2 diabetes do produce insulin. T1D accounts for only
5-15 percent of the total diabetic cases and is usually reported in children and
adolescents. T1D was formerly known as juvenile diabetes. T1D management relies on
providing symptomatic relief and improving quality of life.
The analysts forecast the Global Type 1 Diabetes Market will grow at a CAGR of 6.9
percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Type 1
Diabetes Market for the period 2014-2018. To calculate the market size, the report
considers revenue generated from the sales of various type 1 diabetes management drugs,
which includes insulin-based replacement products and amylin analogues.
The report, the Global Type 1 Diabetes Market 2014-2018, has been prepared based on an
in-depth market analysis with inputs from industry experts. The report covers the Americas
and the EMEA and APAC regions; it also covers the Global Type 1 Diabetes market landscape
and its growth prospects in the coming years. The report also includes a discussion of the
key vendors operating in this market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Global Market Share by Products
08. Product Portfolio
09. Clinical Pipeline Portpolio
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
- Astrazeneca plc - Eli Lilly and Co. - Novo Nordisk A/S - Sanofi-Aventis US LLC - Biodel Inc. - Diamyd Medical AB - DiaVacs Inc. - Generex Biotechnology Corp. - Lexicon Pharmaceuticals Inc. - Macrogenics Inc. - MannKind Corp. - Osiris Therapeutics Inc. - Tolerion Inc. - XOMA Corp.
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets